Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
1 September 2024
How to get a Unitary Patent
1 September 2024
Which states are in the UPC & where will a UP have effect?
16 August 2024
Principles for setting climate targets: A guide for Australian boards
15 August 2024
Less is more — The premise of the biosimilar ‘patent thicket’ bill
22 Juli 2024
Australian Competition & Consumer Commission releases draft sustainability collaboration guidance
19 Juli 2024
Just opt out! Boehringer Ingelheim’s IRA challenge is latest to fail
28 Juni 2024
Helping Life Sciences companies land and expand globally
6 Juni 2024
The Australian Government’s “Closing Loopholes” industrial relations reforms: What they mean for your business
1 Mai 2024
Potential effects of the Inflation Reduction Act on orphan drug development
20 März 2024
Pharma – Strong year ahead
13 März 2024
Generative AI: A bilateral online safety focus for Australia and the UK
30 August 2023
Ghostbusters: In a New Win for Providers, No Surprises Act Rules Struck for Allowing Ghost Rates
Last week, the federal government met its fourth loss in a challenge brought by health care and air ambulance providers against No Surprises Act (NSA) …
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane